{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:25:04Z","timestamp":1790277904694,"version":"4.1.0"},"reference-count":12,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0390-2","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T12:51:00Z","timestamp":1533041460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Delayed onset of neurosarcoidosis after concurrent ipilimumab\/nivolumab therapy"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6258-8194","authenticated-orcid":false,"given":"Irena","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Malinzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K. S.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"issue":"21","key":"390_CR1","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"key":"390_CR2","volume-title":"Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment-na\u00efve patients with advanced melanoma (CheckMate 067)","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chiarion-Silen V, Gonzalez R, et al. Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment-na\u00efve patients with advanced melanoma (CheckMate 067). Washington, DC: Oral presentation presented at, The American Association of Cancer Research (AACR) Annual Meeting; 2017."},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM, Gru AA, et al. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer. 2016;4:94.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"390_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","volume":"40","author":"SB Reddy","year":"2017","unstructured":"Reddy SB, Possick JD, Kluger HM, Galan A, et al. Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J Immunother. 2017;40(8):307\u201311.","journal-title":"J Immunother"},{"key":"390_CR5","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"390_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ccm.2008.03.016","volume":"29","author":"EE Lower","year":"2009","unstructured":"Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med. 2009;29(3):475\u201392.","journal-title":"Clin Chest Med"},{"issue":"9","key":"390_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","volume":"9","author":"I Cleynen","year":"2012","unstructured":"Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9(9):496\u2013503.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"390_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","volume":"193","author":"J Ramstein","year":"2016","unstructured":"Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, Woodruff PG, Bhakta NR, Christian L, Nguyen CP, Antalek BJ. IFN-\u03b3\u2013producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"390_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N, Jalil J, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35.","journal-title":"J Transl Med"},{"issue":"2","key":"390_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/thx.2010.140319","volume":"66","author":"M Facco","year":"2011","unstructured":"Facco M, Cabrelle A, Teramo A, Olivieri V, et al. Sarcoidosis is a Th1\/Th17 multisystem disorder. Thorax. 2011;66(2):144\u201350.","journal-title":"Thorax"},{"issue":"5","key":"390_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","volume":"190","author":"NA Braun","year":"2014","unstructured":"Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190(5):560\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"390_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdw534","volume":"28","author":"AK Salama","year":"2017","unstructured":"Salama AK, Moschos SJ. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann Oncol. 2017;28(1):57\u201374.","journal-title":"Ann Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0390-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:26:22Z","timestamp":1604715982000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0390-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0390-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No formal ethics approval was needed since we were reporting an observation case report. Consent was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained from the patient. He signed a generic consent for this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"77"}}